Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 3, 2026

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the updated Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Chekuri Venkat Ramesh
Digitally signed by Chekuri Venkat Ramesh
Date: 2026.02.03 14:44:24 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa®) from the United States Food and Drug Administration (U.S. FDA)

Hyderabad, India, February 3rd, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today received tentative approval from the U.S. FDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa® by Janssen Biotech Inc.

NATCO's Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy.

Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep'25 as per industry sales data.

Safe Harbor Statement

All brand names and trademarks are the property of their respective owners

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's different manufacturing facilities are approved by several leading regulatory authorities like U.S. FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: r.menon@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences
Email: investors@natcopharma.co.in

Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: https://www.linkedin.com/company/natcopharma